Interleukin-6 and total antioxidant capacity levels following N-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder.
CONCLUSION: Participants with lower IL-6 levels at baseline had a better response to the adjunctive treatment with the mitochondrial-enhancing agents in terms of improvements in MADRS and CGI-I outcomes.
PMID: 32600481 [PubMed - as supplied by publisher]
Source: Acta Neuropsychiatrica - Category: Psychiatry Tags: Acta Neuropsychiatr Source Type: research
More News: Acetylcysteine | Antidoxidants | Bipolar | Brain | Clinical Trials | Depression | Mania | Neurology | Occupational Health | Psychiatry | Study